Full text is available at the source.
Abstract
Combined therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may impact kidney and cardiovascular outcomes in patients with chronic kidney disease.
- The evaluation focuses on kidney, cardiovascular, and mortality outcomes.
- Patients with chronic kidney disease are the primary subjects of interest.
- The comparison is made between combined therapy and SGLT2 inhibitors alone.
- Outcomes of interest include potential benefits from combined therapy.
Simplified